Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:RPRX

Royalty Pharma Q2 2026 Earnings Report

Royalty Pharma logo
$57.17 -1.26 (-2.16%)
Closing price 04:00 PM Eastern
Extended Trading
$57.47 +0.30 (+0.52%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Royalty Pharma EPS Results

Actual EPS
N/A
Consensus EPS
$1.27
Beat/Miss
N/A
One Year Ago EPS
N/A

Royalty Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$758.93 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Royalty Pharma Announcement Details

Quarter
Q2 2026
Date
8/5/2026
Time
Before Market Opens
Conference Call Date
Wednesday, August 5, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Royalty Pharma Earnings Headlines

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
August 3 at 8:15 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337481/0/en/royalty-pharma-appoints-greg-raskin-as-senior-vice-president-head-of-academic-initiatives.html
Royalty Pharma (RPRX) Could Be 40% Undervalued After Its Dividend Decision
July 31 at 1:02 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/royalty-pharma-rprx-could-40-031645447.html
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership with Nvidia - one he believes positions it ahead of Tesla in the autonomous vehicle race. With a market-moving announcement expected on July 31st, Chaikin is urging investors to swap overpriced AI stocks for this under-the-radar name before markets open. He's also releasing a free Hotlist and Hitlist of buy and sell ideas for the second half of 2026.tc pixel
August 3 at 1:00 AM  |  Chaikin Analytics (Ad)
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
July 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/royalty-pharma-acquires-royalty-interest-in-astrazeneca-s-cliramitug-for-up-to-425-million-from-neurimmune-1036350926
Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331241/0/en/royalty-pharma-acquires-royalty-interest-in-astrazeneca-s-cliramitug-for-up-to-425-million-from-neurimmune.html
RPRX Stock Price Prediction
July 20, 2026  |  247wallst.comhttps://247wallst.com/companies/rprx/price-prediction
See More Royalty Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Royalty Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Royalty Pharma and other key companies, straight to your email.

About Royalty Pharma

Royalty Pharma (NASDAQ:RPRX) is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors. Royalty Pharma’s portfolio spans multiple therapeutic areas and stages of product life cycles; revenues are derived from sales of underlying drugs in markets around the world. Its business model is positioned to provide liquidity to biopharma owners while assuming the commercial and regulatory risk associated with future product sales.

Founded by Pablo Legorreta and headquartered in New York, Royalty Pharma completed a public listing on the Nasdaq under the ticker RPRX in 2020. The company operates globally, collecting royalties generated by product sales in multiple geographies and partnering with a wide range of industry participants. Pablo Legorreta, the company’s founder and long-time leader, has been a central figure in Royalty Pharma’s strategy of building a large, diversified portfolio of biopharma royalty assets.

View Royalty Pharma Profile
Earnings Tools